SIETES :: 92796 citas

Resultados de la búsqueda por CONTRAINDICACIONES REFINAR BÚSQUEDA

1.

Anónimo. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. U.S. Food and Drug Administration 2019:21 de junio. [Ref.ID 103134]

2.

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

3.

Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42:abril. [Ref.ID 103082]

4.

Anónimo. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). U.S. Food and Drug Administration 2019:21 de febrero. [Ref.ID 103045]

5.

Christensen J, Pedersen LH, Sun Y, Dreier JW, Brikell I, Dalsqaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Network Open 2019;2:4 de enero. [Ref.ID 103010]

6.

Moore TJ, Mattison DR. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102884]

7.

Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. BMJ 2018;363:14 de noviembre. [Ref.ID 102868]

8.

Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ 2018;361:18 de abril. [Ref.ID 102682]

9.

Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]

10.

Anónimo. Saccharomyces boulardii probiotics: Do not use in critically ill or immunocompromised patients. Estonia . WHO Drug Information 2018;32:19. [Ref.ID 102623]

11.

Iacobucci G. MHRA bans valproate prescribing for women not in pregnancy prevention programme. BMJ 2018;361:k1823. [Ref.ID 102614]

12.

Hirschler B. UK bans Sanofi epilepsy drug without pregnancy prevention plan. Reuters Health News 2018:24 de abril. [Ref.ID 102553]

13.

Anónimo. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone. European Medical Agency 2018:1. [Ref.ID 102552]

14.

Anónimo. Clarithromycin (Biaxin): Drug safety communication - Potential increased risk of heart problems or death in patients with heart disease. U.S. Food and Drug Administration 2018:22 de febrero. [Ref.ID 102539]

15.

Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurology 2018;75:566-72. [Ref.ID 102536]

16.

Herzig SJ, Mosher HJ, Calcaterra SL, Jena AB, Nuckols TK. Improving the safety of opioid use for acute noncancer pain in hospitalized adults: a consensus statement from the Society of Hospital Medicine. J Hosp Med 2018;13:abril. [Ref.ID 102501]

17.

Varga S, Alcusky M, Keith SW, Hegarty SE, Del Canale S, Lombardi M, Maio V. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol 2017;83:2572-80. [Ref.ID 102117]

18.

Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, Ratner R, Barrett-Connor E, Temprosa M, on behalf of the Diabetes Prevention Program(DPP) Research Group. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program.. BMJ Open Diabetes Research & Care 2017;5:1-10. [Ref.ID 102101]

19.

Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzlez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf 2017;26:615-24. [Ref.ID 101961]

20.

Anónimo. Beta blockers and the risk of CV events in type 2 diabetes. Diabetes in Control 2017:29 de julio. [Ref.ID 101936]